2015-Das et al-J Immunol.
"Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo"
Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM.
J Immunol. 2015 Feb 1;194(3):950-9. doi: 10.4049/jimmunol.1401686. Epub 2014 Dec 24.
http://dx.doi.org/10.4049/jimmunol.1401686
This publication takes a broad exploratory approach to investigating the immune response to the checkpoint inhibitors anti-PD-1 and CTLA-4. The authors compare immune cells from patients undergoing monotherapy, combination therapy and sequential therapy. CyTOF is used to take a deeper dive into an immune subset of interest (CD3+CD4+ Ki67+ and CD3+CD8+ Ki67+ cells, figure 2C).
Immuno-oncology is the hottest field in cancer therapy these days. With this approach immune cells are the potentiators of the anti-cancer response. For an immunology buff like me these are very exciting times
Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM.
J Immunol. 2015 Feb 1;194(3):950-9. doi: 10.4049/jimmunol.1401686. Epub 2014 Dec 24.
http://dx.doi.org/10.4049/jimmunol.1401686
This publication takes a broad exploratory approach to investigating the immune response to the checkpoint inhibitors anti-PD-1 and CTLA-4. The authors compare immune cells from patients undergoing monotherapy, combination therapy and sequential therapy. CyTOF is used to take a deeper dive into an immune subset of interest (CD3+CD4+ Ki67+ and CD3+CD8+ Ki67+ cells, figure 2C).
Immuno-oncology is the hottest field in cancer therapy these days. With this approach immune cells are the potentiators of the anti-cancer response. For an immunology buff like me these are very exciting times